Previous 10 | Next 10 |
IceCure Medical Maintains Positive Momentum and Reports Sales Growth for Cryoablation System in First Quarter of 2024 PR Newswire 30% sales growth reflects continued adoption of ProSense® in the U.S. and other global markets Major milestones achieved:...
Orkla ASA ADR (ORKLY) is expected to report for Q1 2024 Cosmos Health Inc. (COSM) is expected to report $-0.14 for Q1 2024 Basilea Pharmaceutica AG Registered Shares (BPMUF) is expected to report for Q1 2024 DCC Plc (DCCPF) is expected to report for Q4 2024 Datatec Ltd ADR (DTTLY)...
IceCure Medical to Report First Quarter 2024 Financial & Operational Results on May 28, 2024 IceCure Medical to Report First Quarter 2024 Financial & Operational Results on May 28, 2024 PR Newswire CAESAREA, Israel , May 21, 2024 /PRNewswire/ -- Ice...
IceCure Medical to Highlight Key Achievements and Provide Business Overview at A.G.P. / Alliance Global Partners' Virtual Healthcare Company Showcase PR Newswire CAESAREA, Israel , May 20, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or...
Independent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense®, Adding to Continued Positive Data Published Globally PR Newswire Study published in the peer reviewed journal Breast Cancer ...
2024-04-17 08:21:19 ET Losers: Arrowroot Acquisition Corp ( AILE ) -34% . Hub Cyber Security Ltd ( HUBC ) -22% . Longeveron ( LGVN ) -18% announces exercise of warrants for $6.2 Million gross proceeds . Sage Therapeutics SAGE -19% after mi...
2024-04-15 10:06:29 ET DENVER, Colo., Apr 15, 2024 ( 247marketnews.com )- IceCure Medical Ltd. (NASDAQ: ICCM ) stated that it submitted final data to the U.S. Food and Drug Administration (“FDA”) requesting marketing authorization for ProSense, which received the FDA...
IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer PR Newswire Data presentation ...
2024-04-03 13:20:27 ET IceCure Medical Ltd. (ICCM) Q4 2023 Earnings Conference Call April 03, 2024, 10:00 AM ET Company Participants Michael Polyviou - EVC Group, Investor Relations Eyal Shamir - Chief Executive Officer Shad Wood - VP of Sales, North American ...
2024-04-03 10:42:06 ET More on IceCure Medical FDA agrees to review IceCure request for De Novo classification Seeking Alpha’s Quant Rating on IceCure Medical Historical earnings data for IceCure Medical Financial information for IceCure Medical ...
News, Short Squeeze, Breakout and More Instantly...
99.74% Recurrence Free Rate for Women with Breast Cancer Treated with IceCure's ProSense® Cryoablation System: Key Findings Delivered at 32nd Annual Meeting of the Japanese Breast Cancer Society PR Newswire Demand for minimally invasive breast cancer treatment was ove...
European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment fo...
U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense™ Cryoablation System with CryoProbes PR Newswire CAESAREA, Israel , July 1, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medic...